Key result
Cardiac ACL loss drives LV dysfunction via altered metabolism, attenuated by IDH1 deletion.
Why the study?
Sustained glucose oxidation during cardiac stress is associated with increased ATP-dependent citrate lyase (ACL) activity and abundance, which supports de novo lipid synthesis. However, how ACL supports cardiac metabolic adaptation and its potential to modulate disease pathophysiology had not yet been investigated.
Does the loss of ATP-dependent citrate lyase (ACL) drive left ventricular dysfunction and metabolic remodeling in the heart?
Does the loss of ATP-dependent citrate lyase (ACL) drive left ventricular dysfunction and metabolic remodeling in the heart?
Loss of ATP-dependent citrate lyase (ACL) in cardiomyocytes disrupts metabolic homeostasis and lipid synthesis, driving left ventricular dysfunction and highlighting ACL as a critical enzyme for maintaining cardiac energy and function.
ACL loss drives metabolic LV dysfunction in mice; leaves open whether ACL/IDH1 targeting alters human cardiomyopathy progression.
BACKGROUND: Metabolic adaptation and maladaptation are hallmarks of the failing heart and may be a target for therapeutic interventions. For example, sustained glucose oxidation during cardiac stress is associated with increased activity and abundance of ACL (ATP-dependent citrate lyase, Acly ), which produces acetyl–coenzyme A (CoA) from citrate and CoA and supports de novo lipid synthesis. However, our understanding of how ACL supports cardiac metabolic adaptation and its potential to modulate disease pathophysiology has not yet been investigated. METHODS: We used human heart tissue samples from healthy donors and patients with nonischemic cardiomyopathy. Next, we used CRISPR (clustered, regularly interspaced short palindromic repeats)/Cas9 (CRISPR-associated 9) gene editing to inactivate Acly in cardiomyocytes of Myh6-Cas9 mice. In vivo positron emission tomography and ex vivo stable isotope tracer labeling were used to quantify metabolic flux changes in response to Acly knockdown. We conducted a multi-omics analysis using RNA sequencing and mass spectrometry–based metabolomics and proteomics. Experimental data were integrated into computational modeling using the metabolic network CardioNet to identify significantly dysregulated metabolic processes at a systems level. RESULTS: We observed reduced ACL abundance and activity in human heart tissue samples from patients with nonischemic cardiomyopathy, which correlated with decreased abundance of Krebs cycle intermediates. Using CRISPR/Cas9 gene editing, we found that cardiac-specific loss of ACL reduces acetyl-CoA synthesis, leading to altered cardiac metabolism characterized by increased glucose uptake and oxidation, impaired energy flux, and elevated AMP to ATP ratios, which collectively promote left ventricular dysfunction. Transcriptomic and mass spectrometry–based metabolomics, as well as proteomic data, reveal compensatory cardiac lipid remodeling and reduced histone 3 acetylation. This metabolic stress promotes activation of AMPK (AMP kinase) and PKA (protein kinase A), which in turn mediates YAP (Yes-associated protein) inhibition through phosphorylation. Stable isotope tracer studies combined with CardioNet simulations demonstrated that increased IDH1 (isocitrate dehydrogenase 1) activity prevents allosteric inhibition of glycolysis from cytosolic citrate accumulation. AAV9-mediated cardiac Idh1 deletion improved cardiac function and energy provision, reducing YAP phosphorylation and restoring downstream YAP signaling. CONCLUSIONS: Our findings suggest that ACL plays a pivotal role in cardiac metabolism through regulating lipid synthesis and cardiac function. Exploiting compensatory pathways of citrate metabolism may improve cardiac function during heart failure.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied Heart failure with reduced ejection fraction (HFrEF). Acly knockdown (ATP-dependent citrate lyase deletion) vs. Wild-type mice / Healthy human donors was evaluated on Left ventricular ejection fraction and metabolic flux. Cardiac-specific loss of ATP-dependent citrate lyase reduces acetyl-CoA synthesis and alters cardiac metabolism, driving left ventricular dysfunction that is attenuated by IDH1 deletion.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: